Author Archives: Jan Paschal

MBX Biosciences (MBX) upsized its IPO to 10.2 million shares – up from 8.5 million shares in the prospectus – and priced the deal at $16.00 – the top of its $14.00-to-$16.00 range – to raise $163.2 million on Thursday night, Sept. 12, 2024. At pricing, MBX Biosciences increased the IPOs size by 20 percent. Shares […]

Galaxy Payroll Group Ltd. (GLXG) of Hong Kong downsized its IPO at pricing – to 1.75 million shares – down from 2.0 million shares in the prospectus – and priced the deal at $4.00, as expected – to raise $7.0 million on Wednesday night, Sept. 11, 2024. Galaxy Payroll’s stock started trading today – Thursday, […]

Bicara Therapeutics (BCAX Proposed), a clinical biotech focused on head and neck squamous cell cancer, increased the size of its IPO to $250 million – up from $200 million initially – in an S-1/A filing after the closing bell on Wednesday, Sept. 11, 2024. The new terms calls for Bicera Therapeutics to offer 14.71 million […]

Bankers priced two small IPOs – Trident Digital Tech Holdings (TDTH) and XCHG Ltd. (XCH) – at or near the low end of their respective price ranges on Monday night, Sept. 9, 2024, to trade today – Tuesday, Sept. 10, 2024 – on the NASDAQ. Here are the pricing details: * Trident Digital Tech Holdings (TDTH) priced its […]

MBX Biosciences (MBX Proposed), a Phase 2 biotech targeting endocrine and metabolic diseases, disclosed the terms for its $127.5 million IPO and launched the deal early today – Monday, Sept. 9, 2024 – for pricing later this week. MBX Biosciences Inc. is offering 8.5 million shares at a price range of $14.00 to $16.00 to […]

Two biotechs – Bicara Therapeutics (BCAX Proposed) and Zenas BioPharma (ZBIO Proposed) – lead the IPO Calendar this week – the week of Sept. 9, 2024 – with plans to raise about $200 million each. Both IPOs are similar in size: Each company plans to offer about 11.8 million shares at a price range of […]

Zenas BioPharma (ZBIO Proposed), a Phase 2/Phase 3 clinical biotech focused on MS and other autoimmune diseases, disclosed the terms for its $199.9 million IPO and launched the deal early today – Friday, Sept. 6, 2024 – for pricing next week. The clinical biotech is offering 11.8 million shares at a price range of $16.00 […]

Cancer biotech Bicara Therapeutics (BCAX Proposed) disclosed the terms for its $200 million IPO early today – Friday, Sept. 6, 2024 – and launched the deal for a NASDAQ debut next week. The biotech, which is targeting head and neck squamous cell cancer, is offering 11.765 million shares at a price range of $16.00 to […]

Get your  motors running: Andretti Acquisition Corp. II (POLEU) and Vine Hill Capital Investment Corp. (VCICU) raised $200 million each on Thursday night, Sept. 5, 2024, to become the first two SPAC IPOs priced in September 2024. Andretti Acquisition II and Vine Hill Capital Investment are expected to start trading today – Friday, Sept. 6, […]

Powell Max (PMAX) cut its small IPO at pricing to 1.43 million shares (1,426,750 shares) and priced the deal at $4.00 – the low end – to raise $5.71 million, the company said today – Thursday, Sept. 5, 2024. Powell Max shares opened today at $4.30 – up 30 cents from their IPO price – in […]